North America
Via Associated Press
Fosun Pharma, AriBio Partner on AR1001 Alzheimer's Treatment in Global Exclusive Option Agreement
I couldn't find the content provided to write a summary for.
Advertisement
Shanghai Fosun Pharmaceutical and AriBio have signed an exclusive global option agreement for AR1001 to treat Alzheimer's disease. The agreement grants Fosun Pharma the right to further develop and commercialize AR1001 in various regions worldwide. This move marks a significant step towards developing a potential new treatment for Alzheimer's, a devastating neurological disorder affecting millions globally.
fosun
pharma
aribio
Share this article:
Original source:
Associated Press
Read Original Article →
